Featured Press Releases

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • 18 Aug 2025

SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb...

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

To Advance Pharmacogenomics in Healthcare, Gene by Gene and myDNA Are Partnering with the University of Glasgow

To Advance Pharmacogenomics in Healthcare, Gene by Gene and myDNA Are Partnering with the University of Glasgow's Living Laboratory

Avenacy Unveils the Launch of Dehydrated Alcohol Injection, USP Vials in the U.S. Market

Avenacy Unveils the Launch of Dehydrated Alcohol Injection, USP Vials in the U.S. Market

Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

  • Complement Therapeutics
  • 08 Oct 2025
Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

  • Zifo Technologies
  • 07 Oct 2025
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

  • Eisai Inc.
  • 07 Oct 2025
CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

  • CareDx, Inc.
  • 06 Oct 2025
Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

  • Niagen Bioscience, Inc
  • 01 Oct 2025
Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

  • Novartis Pharmaceuticals Corporation
  • 01 Oct 2025

Most Popular
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.